Reduced-dosed Rivaroxaban in the Long-term Prevention of Recurrent Symptomatic VTE(Venous Thromboembolism)
Status:
Completed
Trial end date:
2016-11-04
Target enrollment:
Participant gender:
Summary
This is a multicenter, randomized, double-blind, event-driven, superiority study for
efficacy.
Patients with confirmed symptomatic DVT (Deep Vein Thrombosis) or PE (Pulmonary embolism) who
completed 6 or 12 months of treatment of anticoagulation are eligible for this trial